Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gastric Acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    88 result(s) found for: Gastric Acid. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2020-004180-13 Sponsor Protocol Number: OCARINA Start Date*: 2021-10-18
    Sponsor Name:KU Leuven
    Full Title: The effect of obeticholic acid on gut microbiota, gastric motility, accommodation, gastrointestinal peptide in healthy volunteers
    Medical condition: The study will focus on the underlying mechanisms of gastrointestinal motility and gut microbiota in healthy subjects.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10017782 Gastric emptying study PT
    20.1 100000004856 10061247 Intestinal functional disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005387-10 Sponsor Protocol Number: ERY-PAO Start Date*: 2013-03-27
    Sponsor Name:Department of hospital Pharmacy, Medical Centre Haaglanden
    Full Title: Effect of Roux-en-Y gstric bypass surgery in morbidly obese patients on Pharmacokinetics of (Acetyl)salicylic acid and Omeprazole.
    Medical condition: Roux-en-Y gastric bypass (RYGB) surgery is a successful treatment for morbid obesity. In this procedure, a small gastric pouch is created. The duodenum is bypassed by connecting the jejunum to this...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002782-38 Sponsor Protocol Number: Gastro052011 Start Date*: 2012-07-06
    Sponsor Name:INFAI GmbH
    Full Title: Gastromotal 13C-octanoic acid breath test in the diagnosis and evaluation of therapeutic outcome in patients with dyspeptic symptoms and delayed gastric emptying
    Medical condition: Patients with dyspeptic symptoms and delayed gastric emptying.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001859-40 Sponsor Protocol Number: 2019-041 Start Date*: 2020-11-05
    Sponsor Name:Franciscus Gasthuis & Vlietland
    Full Title: PEROPERATIVE TRANEXAMIC ACID IN BARIATRIC FAST TRACK SURGERY TO REDUCE HEMORRAGE RATES
    Medical condition: Morbid obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10059610 Obesity surgery LLT
    21.0 100000004861 10027966 Morbid obesity LLT
    21.1 100000004865 10068900 Bariatric surgery LLT
    20.0 100000004865 10070978 Sleeve gastrectomy LLT
    20.0 100000004856 10019542 Hemorrhage gastric LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001069-18 Sponsor Protocol Number: CA224-060 Start Date*: 2018-09-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NO (Completed) BE (Completed) PL (Completed) AT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024379-15 Sponsor Protocol Number: PaFLO Start Date*: 2011-09-19
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.
    Medical condition: We will treat patients with locally advanced or metastatic gastric cancer or adenocarcinoma of the gastro-esophageal junction with no curable treatment option.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10017770 Gastric carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004896-30 Sponsor Protocol Number: CA224-051 Start Date*: 2018-07-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo i...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) PL (Completed) GR (Ongoing) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014895-23 Sponsor Protocol Number: #0038 Start Date*: 2013-02-01
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Phase II clinical trial of a sequential therapy involving the FLOT regiment in palliative first-line treatment followed by AIO plus irinotecan in second-line treatment combined with supportive pare...
    Medical condition: Advanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junction
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004997-23 Sponsor Protocol Number: M0003-C201 Start Date*: 2007-11-23
    Sponsor Name:Movetis NV
    Full Title: An exploratory, double-blind, randomized, stratified, placebo-controlled, repeated dose trial to investigate the efficacy of M0003 on symptoms suggestive for gastroparesis, to assess the pharmacody...
    Medical condition: Symptoms suggestive for gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000624-10 Sponsor Protocol Number: AIO-STO-0217 Start Date*: 2018-02-27
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTE...
    Medical condition: inoperable, advanced or metastatic untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001141 Adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER2 positive gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001402-23 Sponsor Protocol Number: YO28322 Start Date*: 2012-09-07
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPL...
    Medical condition: GASTROESOPHAGEAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) IT (Completed) BE (Completed) GB (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000308-16 Sponsor Protocol Number: prucalopride1 Start Date*: 2011-10-24
    Sponsor Name:UZ Leuven
    Full Title: Prucalopride versus Placebo in Idiopathic and Diabetic Gastroparesis
    Medical condition: Patients with delayed gastric emptying (t1/2 for solids ≥ 109 min) either from idiopathic or diabetic origin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    14.0 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006731-45 Sponsor Protocol Number: PB-2006-01 Start Date*: 2007-04-26
    Sponsor Name:Køge Sygehus
    Full Title: PPI-Rebound-Trial
    Medical condition: This is a healthy volunteer trial designed to investigate if long-term treatment with nexium is the cause of a clinically significant acid rebound phenomenon. The intended indication for nexium is ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008175-34 Sponsor Protocol Number: MOT111809 Start Date*: 2009-03-31
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor A...
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051153 Diabetic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022793-14 Sponsor Protocol Number: AB10007 Start Date*: 2011-08-05
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masi...
    Medical condition: gastric or gastro-oesophageal junction metastatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063916 Metastatic gastric cancer PT
    12.1 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001018-76 Sponsor Protocol Number: CA209-649 Start Date*: 2016-10-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Ga...
    Medical condition: Gastric or Gastroesophageal Junction Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Ongoing) PL (Ongoing) HU (Ongoing) DE (Restarted) PT (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004624-38 Sponsor Protocol Number: BOT112-02 Start Date*: 2020-06-11
    Sponsor Name:Highlight Therapeutics, S.L
    Full Title: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophagea...
    Medical condition: Colorectal cancer or gastric/gastro-oesophageal junction cancer with liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003950-24 Sponsor Protocol Number: EOX1.4 Start Date*: 2012-02-14
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHASE II TRIAL OF PALLIATIVE EPIRUBICIN, OXALIPLATIN & CAPECITABINE (EOX) CHEMOTHERAPY COMBINED WITH OMEGA-3 FISH OIL INFUSION (OMEGAVEN) IN PATIENTS WITH OESOPHAGO-GASTRIC CARCINOMA
    Medical condition: Unresectable oesophageal and/or gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000273-81 Sponsor Protocol Number: UC-GIG-2203 Start Date*: 2022-09-13
    Sponsor Name:UNICANCER
    Full Title: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurre...
    Medical condition: Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016962-10 Sponsor Protocol Number: GOIRC 02/2009 Start Date*: 2010-02-12
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: First Line Dose-Dense Chemotherapy With Docetaxel, Cisplatin, Folinic Acid and 5- Fluorouracil plus Panitumumab in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastro-Esoph...
    Medical condition: Patients with metastatic or locally advanced not resectable cancer of the stomach or gastro-esophageal junction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017758 PT
    9.1 10030176 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 15 22:05:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA